Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
CAMBRIDGE, Mass., April 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 4:20 p.m. ET in New York City.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
